Adenosine A2A receptor agonist improves cardiac dysfunction from pulmonary ischemia-reperfusion injury

T. Brett Reece, Victor E. Laubach, Curtis G. Tribble, Thomas S. Maxey, Peter I. Ellman, Patrick S. Warren, Andrew M. Schulman, Joel Linden, John A. Kern, Irving L. Kron

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

Background. Ischemia-reperfusion (IR) injury negatively impacts patient outcome in lung transplantation. Clinically, we observed that lung transplant patients with ischemia-reperfusion injury tend to have cardiac dysfunction. Previous studies have shown that ATL-146e (4-{3-[6-amino-9-(5-ethylcarbamoyl-3, 4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl} -cyclohexanecarboxylic acid methyl ester), a selective adenosine A2A receptor agonist, reduces lung inflammation after ischemia-reperfusion. We hypothesized that pulmonary ischemia-reperfusion causes secondary heart dysfunction and ATL-146e will improve this dysfunction. Methods. We utilized an in vivo rabbit lung ischemia-reperfusion model. The Sham group underwent 120 minutes single lung ventilation. The IR and ATL groups underwent 90 minutes right lung ischemia with 30 minutes right lung reperfusion. The ATL-146e was given intravenously to the ATL group during reperfusion. Cardiac output and arterial blood gases were monitored, and neutrophil sequestration was measured by myeloperoxidase activity. Results. Upon reperfusion, cardiac output (mL/min) significantly dropped in the IR and ATL groups. By 15 minutes reperfusion, cardiac output in the ATL group improved significantly over the IR group and remained significant thereafter. Lung myeloperoxidase activity was significantly reduced by ATL-146e. Although never hypoxemic, arterial oxygenation was lower in the IR and ATL groups while central venous pressures and mean arterial pressures were similar among groups. A separate experiment demonstrated that reperfusion with the antioxidant N-(2-mercaptopropionyl)glycine prevented cardiac dysfunction. Conclusions. Pulmonary ischemia-reperfusion causes cardiac dysfunction independent of preload, afterload, and oxygenation. The ATL-146e improves this dysfunction presumably by the antiinflammatory effects of adenosine A2A receptor activation on neutrophils. One likely mechanism involves the release of oxidants from the ischemic lung upon reperfusion, which has immediate negative effects on the heart.

Original languageEnglish (US)
Pages (from-to)1189-1195
Number of pages7
JournalAnnals of Thoracic Surgery
Volume79
Issue number4
DOIs
StatePublished - Apr 2005
Externally publishedYes

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Adenosine A<sub>2A</sub> receptor agonist improves cardiac dysfunction from pulmonary ischemia-reperfusion injury'. Together they form a unique fingerprint.

  • Cite this

    Reece, T. B., Laubach, V. E., Tribble, C. G., Maxey, T. S., Ellman, P. I., Warren, P. S., Schulman, A. M., Linden, J., Kern, J. A., & Kron, I. L. (2005). Adenosine A2A receptor agonist improves cardiac dysfunction from pulmonary ischemia-reperfusion injury. Annals of Thoracic Surgery, 79(4), 1189-1195. https://doi.org/10.1016/j.athoracsur.2004.09.038